This condition is caused by a protozoal parasite that functions as a distinct human pathogen [1]. It is recognized as the predominant agent responsible for recurrent malaria infections across diverse geographic zones [1]. Modern clinical assessments have reclassified its historical perception, confirming that it actively drives significant morbidity and fatality rates comparable to other major malaria species [2].
Disease overview
Parasitic Evidence-backed information EN 5/7 applicable sections · ZH 5/7 applicable sections Updated Oct 23, 2026
Plasmodium vivax malaria is a protozoan infection representing the most widespread cause of recurring malaria globally [1]. Although historically classified as less virulent than competing species, contemporary evidence demonstrates its capacity to produce severe pathology and substantial mortality [2][1]. The disease burden continues to shift across endemic regions, with resurgence noted in parts of Africa and South America amid broader health system disruptions [3]. Control efforts remain constrained by the toxicity profiles of established antirelapse therapies and evolving vector resistance [4][3].
Read the full clinical and epidemiological profile 6
Infections frequently involve haematological alterations, including marked declines in haemoglobin concentration that require careful monitoring during therapeutic courses [4][5]. Severe manifestations commonly encompass acute respiratory distress syndrome and pronounced splenomegaly, both of which correlate with elevated case fatality [2][1]. Patients may also experience gastrointestinal disturbances such as vomiting, anorexia, or diarrhoea, particularly during multi-day treatment protocols [5]. Clinical indicators like reduced baseline haemoglobin, lower body temperature, and diminished oxygen saturation significantly predict adverse outcomes in complicated presentations [2].
Malaria constitutes a major global public health challenge, predominantly caused by Plasmodium falciparum and Plasmodium vivax, and accounts for nearly half a million deaths each year [3]. The disease burden is actively increasing in several African and South American regions, with 2021 data reporting an estimated 247 million cases and 619,000 fatalities across 84 endemic nations [4].
The disease is propagated by Anopheles mosquito vectors, which continue to develop physiological and behavioural resistance to insecticides, thereby complicating efforts to interrupt transmission and control spread [4].
Strategic mitigation emphasizes the systematic deployment of intermittent preventive therapies targeting pregnant individuals and infants, supplemented by seasonal chemoprevention frameworks [3]. International health guidelines additionally endorse the integration of pre-erythrocytic immunizations to further diminish community transmission and illness severity [3]. Long-term elimination objectives depend on synchronized mass drug administration programs, optimized vector management strategies, and sustained pharmaceutical innovation to overcome existing therapeutic barriers [3].
- 1 Wikipedia contributors. Plasmodium vivax [Internet]. Wikipedia. cited 3 Sept 2026. Available from: https://en.wikipedia.org/wiki/Plasmodium_vivax
- 2 Val F et al. Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis. Am J Trop Med Hyg. 2017 Sep. PMID: 28722625. doi: 10.4269/ajtmh.17-0131. PubMed: https://pubmed.ncbi.nlm.nih.gov/28722625/
- 3 Poespoprodjo JR et al. Malaria. Lancet. 2023 Dec 16. PMID: 37924827. doi: 10.1016/S0140-6736(23)01249-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/37924827/
- 4 Rajasekhar M et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024 Feb. PMID: 37748497. doi: 10.1016/S1473-3099(23)00431-0. PubMed: https://pubmed.ncbi.nlm.nih.gov/37748497/
- 5 Commons RJ et al. Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. Lancet Child Adolesc Health. 2024 Nov. PMID: 39332427. doi: 10.1016/S2352-4642(24)00210-4. PubMed: https://pubmed.ncbi.nlm.nih.gov/39332427/
- B51
- 1F40
Loading current data…
Country surveillance trends
Choose a country, source, and measure. Each line retains its published reporting period and definition.
Loading data…
Coverage
Reporting countries and regions
The map shows reporting coverage. Select a measure or open a shaded location to inspect its data.
Loading current data…
Surveillance pattern
Year × month seasonality by country
Review one country’s published monthly values by year. Empty cells indicate values the source did not publish.
Research Radar
Recent related research
Transgenic Plasmodium berghei expressing P. vivax pre-erythrocytic antigens SSP3 and SPECT1 to elucidate their efficacy towards vaccine development
PLOS Neglected Tropical Diseases
Delayed diagnosis of Plasmodium vivax malaria and associated factors among Thai patients and patients from neighboring countries at the Hospital for Tropical Diseases, Bangkok, Thailand
Infection
Evaluation of immunogenicity and efficacy of a Plasmodium vivax nanoparticle vaccine in mice
Vaccine
Severe Plasmodium vivax Malaria Complicated by Secondary Hemophagocytic Lymphohistiocytosis, Disseminated Intravascular Coagulation, and Acute Pancreatitis: A Case Report.
Clinical case reports
Slide positivity, trends, and risk factors of febrile Plasmodium vivax malaria along the Thailand-Myanmar border, 2018–2023
Infectious Diseases of Poverty
Showing 5 of 13 related publications.
Literature links are provided for discovery and do not alter or validate the surveillance series above.
Loading official alerts…
Downloads and methods
Choose a time range and download CSV, JSON or XLSX files.